Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3126327 | 0.87 | ALDH1A1 (0.41) | MEN1ALDH1A1KMT2AGRIN2DGRIN3B | |
| SCHEMBL31123487 | 0.82 | MEN1 (0.35) | MEN1ALDH1A1KMT2AGRIN2DGRIN3B | |
| SCHEMBL3126332 | 0.79 | ALDH1A1 (0.40) | SCN9AMEN1ALDH1A1KMT2AGRIN2D | |
| SCHEMBL19929334 | 0.79 | PKM (0.39) | SCN9AMEN1ALDH1A1KMT2A | |
| SCHEMBL919449 | 0.79 | CA12 (0.42) | MEN1ALDH1A1KMT2AGRIN2DGRIN3B | |
| SCHEMBL12869523 | 0.78 | MEN1 (0.33) | MEN1ALDH1A1KMT2A | |
| SCHEMBL19929343 | 0.74 | ALDH1A1 (0.51) | MEN1ALDH1A1KMT2A | |
| SCHEMBL4803060 | 0.74 | MEN1 (0.37) | MEN1ALDH1A1KMT2AGRIN2DGRIN3B | |
| SCHEMBL15535903 | 0.70 | ALDH1A1 (0.45) | SCN9AALDH1A1P2RX7GRIN2DGRIN3B | |
| SCHEMBL21753438 | 0.70 | GRIN2D (0.56) | MEN1KMT2AP2RX7GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402712-B2 | Adamantyl vinyl ether compound and production process for the same | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20050004391-A1 | Adamantyl vinyl ether compound and production process for the same | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1486480-A1 | Adamantyl vinyl ether compound and production process for the same | Idemitsu Petrochemical Co., Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004391-A1 | Adamantyl vinyl ether compound and production process for the same | NOTUM, CYP4A11, CYP4F11 | SCN9A 2815/4885MEN1 1442/4885ALDH1A1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.